【表】
2024年10月29日
アムジェンの乾癬疾患啓発活動のアンバサダーにフリーアナウンサーの高島彩さんが就任
～「見つけよう、あなたの乾癬治療」～
10月29日の世界乾癬デーに疾患啓発動画を公開し、活動を開始
アムジェン株式会社（本社：東京、代表取締役社長：スザナ・ムルテイラ、以下「アムジェン」）はこのたび、フリーアナウンサーの高島彩さんをアンバサダーとしてお迎えし、乾癬患者さん一人ひとりに寄り添った治療のサポートを目的として、乾癬の疾患啓発活動を実施いたします。本活動では、高島彩さんが出演する動画の公開、アムジェンの疾患啓発Webサイト「乾癬パートナーズ（https://www.kansen-partners.jp/）」のコンテンツ配信、病院内へのポスターの掲出等を通じて、「見つけよう、あなたの乾癬治療」というメッセージとともに、乾癬に対する正しい理解の促進を目指します。
【画像：https://kyodonewsprwire.jp/img/202410218457-O2-U7j902J1】
日本における乾癬患者さんの数は、40〜50万人以上と推計されています1,2。乾癬は完治が難しく、また症状が良くなったり悪化したりを繰り返すため、多くの患者さんは症状の改善を望みながらも、長期間にわたる治療を続けることが困難となり、治療を中断してしまうことがあります。また、自分に適した治療法を見つけられずに諦めてしまうことも少なくありません。
高島彩さんは約20年前に乾癬に罹患し、患者として多くの悩みを抱えてきました。高島彩さんの「同じ境遇にある乾癬患者さんの気持ちに寄り添いながら、正しい疾患情報を届けたい」という想いとアムジェンの活動目的が合致し、今回アンバサダーとしてお迎えすることになりました。
この活動を通じて、乾癬患者さんに多様な治療選択肢があることをお伝えするとともに、個々の患者さんに適した治療法を見つけるためには、日々の乾癬に関する悩みを医師や看護師に相談し、コミュニケーションを取りながら治療を進めていくことが重要であることを改めて発信していきます。
アムジェンは、「To serve patients – 患者さんのために、今できるすべてを」というミッションのもと、革新的な治療薬の開発と提供にとどまらない、患者さんの生活や治療をトータルサポートするための活動に取り組んでまいります。
＜高島彩さんコメント＞
「私自身も、約20年前に乾癬に罹患し、症状に対する悩みはもちろんのこと、この先どのような治療が最適なのか、不安に思うこともたくさんありました。元々医師に自分の症状や気持ちを伝えるのが得意ではなく、なんとか処方いただいた薬で抑えていましたが、疾患と長く付き合っていく中で、前向きに治療へ取り組むためには、乾癬のことを自分自身で正しく理解し、医療関係者の皆さまと沢山コミュニケーションをとることが大切であったと実感しております。
これから、乾癬という疾患が一人でも多くの人に理解いただけるよう、また、患者さんお一人おひとりがご自身に合った治療法と出会えるよう、アムジェンと共に疾患啓発に努めていければと思っております。」
＜高島彩さんプロフィール＞
【表】
◆高島彩さんが出演する疾患啓発動画 概要
動画は高島彩さんがリラックスした自然な雰囲気の中でインタビューに応じるシーンから始まります。高島彩さんは、ご自身の経験を交えながら、乾癬には塗り薬や注射に加えて、飲み薬など、個々の患者さんに適した様々な治療法があることを語ります。最後は、「見つけよう、あなたの乾癬治療」というメッセージとともに、未来を前向きに見据える表情の高島彩さんが、乾癬患者さん一人ひとりがご自身の疾患について正しく理解し、自分に合った治療法を見つけるために、乾癬の悩みや不安を改めて医師に相談することを促す内容で締めくくられます。
動画公開日：2024年10月29日（火）～
公開URL ：https://www.kansen-partners.jp/find-your-psoriasis-treatment-with-aya
＜ストーリーボード＞
【画像：https://kyodonewsprwire.jp/img/202410218457-O4-wFD65P2O】
尋常性乾癬について
乾癬は、免疫反応の異常によって発症する全身性の慢性炎症性疾患です3,4。日本における罹患者は40～50万人以上と推計されています1,2。乾癬は主に5つの病型に分かれますが、尋常性乾癬が最も多くみられる病型で、乾癬患者さんの約90%を占めています5。銀白色の鱗屑に覆われた境界鮮明な紅班が特徴です。乾癬の症状は、肘や膝などの関節付近で確認されることが多く、頭皮や爪にも症状が現れることがあります。また84%の患者さんが痒みを感じているという報告もあります6。こうした状況は、QOLに悪影響が及んでいると考えられ、乾癬患者さんの身体的および精神的なQOLスコアは、がんや心筋梗塞の患者さんより低いとする報告もあります7。
アムジェン株式会社について
アムジェン株式会社は、世界最大規模の独立バイオテクノロジー企業である米国アムジェン社の日本法人です。アムジェン株式会社では、循環器疾患、がん、骨疾患、炎症・免疫性疾患、神経疾患、希少疾患を始めとするアンメット・メディカル・ニーズが高い領域に焦点を絞り、「To serve patients – 患者さんのために、今できるすべてを」というミッションのもと、臨床開発から販売までの活動を行っています。詳細については https://www.amgen.co.jp/ をご覧になるか、https://www.facebook.com/amgenjapan をフォローしてください。
Amgen Forward-Looking Statements
This news release contains forward-looking statements that are based on the current expectations and beliefs of Amgen. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including any statements on the outcome, benefits and synergies of collaborations, or potential collaborations, with any other company (including BeiGene, Ltd. or Kyowa Kirin Co., Ltd.), the performance of Otezla® (apremilast) (including anticipated Otezla sales growth and the timing of non-GAAP EPS accretion), our acquisitions of Teneobio, Inc., ChemoCentryx, Inc., or Horizon Therapeutics plc (including the prospective performance and outlook of Horizon's business, performance and opportunities and any potential strategic benefits, synergies or opportunities expected as a result of such acquisition, and any projected impacts from the Horizon acquisition on our acquisition-related expenses going forward), as well as estimates of revenues, operating margins, capital expenditures, cash, other financial metrics, expected legal, arbitration, political, regulatory or clinical results or practices, customer and prescriber patterns or practices, reimbursement activities and outcomes, effects of pandemics or other widespread health problems on our business, outcomes, progress, and other such estimates and results. Forward-looking statements involve significant risks and uncertainties, including those discussed below and more fully described in the Securities and Exchange Commission reports filed by Amgen, including our most recent annual report on Form 10-K and any subsequent periodic reports on Form 10-Q and current reports on Form 8-K. Unless otherwise noted, Amgen is providing this information as of the date of this news release and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise.
No forward-looking statement can be guaranteed and actual results may differ materially from those we project. Our results may be affected by our ability to successfully market both new and existing products domestically and internationally, clinical and regulatory developments involving current and future products, sales growth of recently launched products, competition from other products including biosimilars, difficulties or delays in manufacturing our products and global economic conditions. In addition, sales of our products are affected by pricing pressure, political and public scrutiny and reimbursement policies imposed by third-party payers, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and healthcare cost containment. Furthermore, our research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. We or others could identify safety, side effects or manufacturing problems with our products, including our devices, after they are on the market. Our business may be impacted by government investigations, litigation and product liability claims. In addition, our business may be impacted by the adoption of new tax legislation or exposure to additional tax liabilities. If we fail to meet the compliance obligations in the corporate integrity agreement between us and the U.S. government, we could become subject to significant sanctions. Further, while we routinely obtain patents for our products and technology, the protection offered by our patents and patent applications may be challenged, invalidated or circumvented by our competitors, or we may fail to prevail in present and future intellectual property litigation. We perform a substantial amount of our commercial manufacturing activities at a few key facilities, including in Puerto Rico, and also depend on third parties for a portion of our manufacturing activities, and limits on supply may constrain sales of certain of our current products and product candidate development. An outbreak of disease or similar public health threat, such as COVID-19, and the public and governmental effort to mitigate against the spread of such disease, could have a significant adverse effect on the supply of materials for our manufacturing activities, the distribution of our products, the commercialization of our product candidates, and our clinical trial operations, and any such events may have a material adverse effect on our product development, product sales, business and results of operations. We rely on collaborations with third parties for the development of some of our product candidates and for the commercialization and sales of some of our commercial products. In addition, we compete with other companies with respect to many of our marketed products as well as for the discovery and development of new products. Discovery or identification of new product candidates or development of new indications for existing products cannot be guaranteed and movement from concept to product is uncertain;consequently, there can be no guarantee that any particular product candidate or development of a new indication for an existing product will be successful and become a commercial product. Further, some raw materials, medical devices and component parts for our products are supplied by sole third-party suppliers. Certain of our distributors, customers and payers have substantial purchasing leverage in their dealings with us. The discovery of significant problems with a product similar to one of our products that implicate an entire class of products could have a material adverse effect on sales of the affected products and on our business and results of operations. Our efforts to collaborate with or acquire other companies, products or technology, and to integrate the operations of companies or to support the products or technology we have acquired, may not be successful. There can be no guarantee that we will be able to realize any of the strategic benefits, synergies or opportunities arising from the Horizon acquisition, and such benefits, synergies or opportunities may take longer to realize than expected. We may not be able to successfully integrate Horizon, and such integration may take longer, be more difficult or cost more than expected. A breakdown, cyberattack or information security breach of our information technology systems could compromise the confidentiality, integrity and availability of our systems and our data. Our stock price is volatile and may be affected by a number of events. Our business and operations may be negatively affected by the failure, or perceived failure, of achieving our environmental, social and governance objectives. The effects of global climate change and related natural disasters could negatively affect our business and operations. Global economic conditions may magnify certain risks that affect our business. Our business performance could affect or limit the ability of our Board of Directors to declare a dividend or our ability to pay a dividend or repurchase our common stock. We may not be able to access the capital and credit markets on terms that are favorable to us, or at all.
注意事項（アムジェン株式会社）
このニュースリリースに含まれている医薬品（開発中のものを含む）に関する情報は、宣伝広告、医学的アドバイスを目的とするものではありません。
###
References
1. Kubota K, et al BMJ 2015 Jan BMJ Open 2015 Jan 14;5(1): e006450.
2. 照井 正 他: 臨床医薬, 30(3): 279-285, 2014.
3. Nestle FO, et al. N Engl J Med. 2009;361:496-509.
4. Lowes MA, et al. Annu Rev Immunol. 2014;32:227-255.
5. 飯塚 ⼀：⽇本⽪膚科学会雑誌, 116: 1285-1293, 2006.
6. Yosipovitch et al. Br J Dermatol. 2000;143: 969.
7. Rapp SR, et al. J Am Acad Dermatol. 41: 401-407, 1999.
